CURRICULUM VITAE

 

PERSONAL INFORMATION

Name:  Michael E. Jung

Date and Place of Birth:  May 14, 1947 in New Orleans, Louisiana

Marital Status:  Married, wife Alice

Mailing Address:   Department of Chemistry

                               University of California

                               Los Angeles, CA 90095-1569

Telephone:  (310) 825-7954              FAX: (310) 206-3722

email: jung@chem.ucla.edu

 

EDUCATIONAL BACKGROUND

Distinguished Professor Further Above Scale, UCLA, 2010 - present

Distinguished Professor, UCLA, 2004 - 2010

Professor Further Above Scale, UCLA, 2002 - 2004

Professor Above Scale, UCLA, 1998 - 2002

Professor VIII, UCLA, 1996 - 1998

Professor VII, UCLA, 1994 - 1996

Professor VI, UCLA, 1992 - 1994

Professor V, UCLA, 1990 - 1992

Professor IV, UCLA, 1988 - 1990

Professor III, UCLA, 1987 - 1988

Professor II, UCLA, 1985 - 1987

Professor I, UCLA, 1983 - 1985

Associate Professor III, UCLA, 1981 - 1983

Associate Professor I, UCLA, 1979 - 1981

Assistant Professor IV, UCLA, 1977 - 1979

Assistant Professor III, UCLA, 1976 - 1977

Assistant Professor II, UCLA, 1974 - 1976

NATO Postdoctoral Fellowship, Eidgenössische Technische Hochschule, Zürich, Switzerland, 1973 - 1974; Albert Eschenmoser, advisor

Ph.D., Columbia University, New York, New York, 1973; Gilbert Stork, advisor

B.A., Summa cum laude, Rice University, Houston, Texas, 1969; Richard Turner, advisor

 

PROFESSIONAL AFFILIATION

 

American Chemical Society, 1969 - present

The Chemical Society, 1971 - present

Phi Lambda Upsilon, 1968 - present

UCLA Cancer Center, 1975 - present

Division of Organic Chemistry, ACS, 1975 - present

Division of Medicinal Chemistry, ACS, 1975 - present

Sigma Xi, 1977 - present

American Men and Women of Science, Chemistry, 1977 - present

American Association for the Advancement of Science, 1979 - present

Molecular Biology Institute, UCLA, 2004 - present

California NanoSystems Institute (CNSI), UCLA, 2006 - present.

Director, UCLA Biosciences Synthetic Chemistry Core Facility, 2006 - present.

 

COWORKERS

 

Current:  7 graduate students, 10 postdoctoral associates, 1 undergraduate researcher

Former:  83 PhD's granted, 7 MS's granted, 104 postdoctoral associates, 40 undergraduates, 21 research associates and technicians

 


HONORS AND AWARDS

Professional - University of California


2011

Plenary Lecturer, First Mexican Meeting on Pure and Applied Chemistry, Mexico City

2011

Plenary Lecturer, USC Stauffer Symposium, Los Angeles, CA

2011

Plenary Lecturer, ACS Award Symposium Award in Industrial Chemistry, Anaheim, CA

2010

Plenary Lecturer, 14th International Congress on Hormonal Steroids, and Hormones and Cancer, Edinburgh

2010

Dr. Paul Janssen Lecture Series in Organic Chemistry Lecturer, Johnson & Johnson Pharmaceeutical R&D, Beerse, Belgium
2009 Herbert Newby McCoy Award Recipient, UCLA
2009 Plenary Lecturer, ZaCh Systems Symposium on Organic Synthesis, Paris
2009 Plenary Lecturer, Center for Cancer Research Eminent Lecture Series, National Cancer
2008 Organic Synthesis Symposium, 43rd Mexican Chemical Society National Meeting, Tijuana, Mexico
2008 Plenary Lecturer, Symposium in honor of Victor Marquez, American Chemical Society National Meeting, Philadelphia, PA
2008 Plenary Lecturer, Chemical Insights into Biological Processes, Center for Cancer Research, National Cancer Institute, Frederick, MD
2008 Plenary Lecturer, Symposium on Organic Synthesis, 91st National Meeting of the Canadian Society for Chemistry, Edmonton, Canada
2007 Wolfrom Award Symposium in honor of Muthiah Manoharan, 234th ACS National Meeting, Boston, MA
2006 Boehringer-Ingelheim Lecturer, University of British Columbia, Vancouver
2004 Plenary Lecturer, Ischia Advanced School of Organic Chemistry, Ischia, Italy
2004 Bristol-Myers Squibb Lecturer, University of Puerto Rico, Rio Piedras, PR
2003 Invited Professor, Université Pierre et Marie Curie, Paris
2002 Auspex Horizon Award, Auspex Pharmaceutical Co., Inc., San Diego, CA
2002 Plenary Lecturer, 60th Anniversary International Symposium on Organic Synthesis, Tokyo, Japan
2001 Plenary Lecturer, First International Symposium on Asymmetric Synthesis, Universidad Nacional Autonoma de Mexico (UNAM), Mexico City
1999 Plenary Lecturer, Japan Pharmaceutical Society, Tokushima, Japan
1999 Plenary Lecturer, Japan Chemical Society, Tokyo, Japan
1998 Plenary Lecturer, 21st Gulf Coast Chemistry Conference, Pensacola, FL
1998 Invited Lecturer, XIII International Round Table on Nucleosides, Nucleotides and Their Biological Applications, Montpellier, France
1998 Invited Lecturer, 19th International Carbohydrate Symposium, La Jolla, CA
1998 Plenary Lecturer, Western Switzerland Lecture Tour
1998 Plenary Speaker, Spring Meeting, French Chemical Society, Paris
1998 Plenary Lecturer, Robert A. Welch Foundation
1997 Plenary Speaker, 2nd AFMC International Medicinal Chemistry Symposium (AIMECS 97), Seoul
1997 Invited Lecturer, 16th International Congress of Heterocyclic Chemistry, Montana State University, Bozeman, MT
1995 American Chemical Society Arthur C. Cope Scholar Award
1995 Plenary Lecturer, Gordon Conference on Purines, Pyrimidines, and Other Related Substances
1995 Plenary Lecturer, 5th French American Chemical Society (FACS) Conference
1992 Hanson-Dow Teaching Award, UCLA
1991 Herbert Newby McCoy Award Recipient, UCLA
1991 Fujii-Ohtsuka Professor, University of Tokushima, Tokushima, Japan
1988 Plenary Lecturer, 3rd Nozaki Conference, Sagamihara, Japan
1987 Glenn T. Seaborg Award Recipient
1987 Plenary Lecturer, Gordon Conference on Natural Products Chemistry
1987 Plenary Lecturer, Gordon Conference on Organic Reactions and Processes
1986 Inaugural UCLA Gold Shield Faculty Prize
1985 Plenary Lecturer, 9th Oxford Symposium on Organic Synthesis, Oxford
1982 Plenary Lecturer, 4th International Conference on Organic Synthesis, Tokyo
1981 Invited Participant, Twelfth Annual Workshop on Organic Synthesis in Natural Products Chemistry, Pingree Park, Colorado
1981 Plenary Lecturer, French Chemical Society Meeting, Paris (Spring)
1980 Fulbright-Hays Grant, U.S. Research Scholar Award
1980 American Cyanamid Young Researcher Award
1980 Plenary Lecturer, Gordon Conference on Organometallic Chemistry
1979 Alfred P. Sloan Foundation Research Fellow
1979 Camille and Henry Dreyfus Teacher-Scholar Grantee
1977 Eli Lilly Grantee
1978 University Distinguished Teaching Award
1978 Invited Speaker, Symposium for Creative Work in Synthetic Organic Chemistry, 175th ACS National Meeting, Anaheim
1978 Plenary Lecturer, 5th Annual Conference on Organosilicon Chemistry
1977 Invited Participant, Eight Annual Workshop on Organic Synthesis in Natural Products Chemistry, Dartmouth College Minary Conference Center, NH
1975 UCLA Summer Faculty Fellow

Postgraduate - Eidgenössische Technische Hochschule


1973        NATO Postdoctoral Fellow


Graduate - Columbia University

1973        Hammett Award for Research  

1969-73   National Studies Foundation Predoctoral Fellow


Undergraduate - Rice University

1968        Phi Beta Kappa

1967-69   ARCS Foundation Scholar 

1967-68   Blanche White Honor Scholar

1966-67   William Marsh Rice Scholar

1965-66   University Prize Scholar

 


FOUNDER

 

Aragon Pharmaceuticals, Inc., La Jolla, CA, 2009 - present

MAX BioPharma, Inc., Los Angeles, CA, 2011 - present


MEMBERSHIP ON SCIENTIFIC ADVISORY BOARDS

 

Auspex Pharmaceuticals, Inc., Vista, CA, 2004 - present
Trius Pharmaceuticals, San Diego, CA, 2006 - present
Neurocrine Biosciences, Inc., La Jolla, CA, 2003 - 2009

Medivation, Inc., San Francisco, CA, 2006 - 2009

Encore Pharmaceutical, Inc., Loma Linda, CA, 1998 - 2002

 

CONSULTANTSHIPS

 

Isis Pharmaceuticals, Carlsbad, CA, 1995 - present

ORIL, S.A., Bolbec, France, 1996 - present

Gilead Science Process Chemistry, Foster City, CA, 1996 - present

Gilead Science Medicinal Chemistry, Foster City, CA, 1999 - present

Institut de Recherche Servier, Servier Pharmaceutical Inc., Suresnes, France, 2000 - present

DuPont Crop Protection, Newark, DE, 2002 - present

Alnylam, Inc., Cambridge, MA, CA, 2003 - present

Cylene Pharmaceuticals, San Diego, CA, 2003 - present.

Celgene Pharmaceutical, Inc., San Diego, CA, 2003 - present

Auspex Pharmaceuticals, Inc., Vista, CA, 2004 - present

ArQule Pharmaceutical Inc., Woburn, MA, 2005 - present

Abraxis BioSciences, Inc., Santa Monica, CA, 2005 - present

Trius Pharmaceuticals, San Diego, CA 2006 - present

ZaCh System, Inc. (formerly PPG-Sipsy), Angers, France 2007 - present

Prestwick Chemicals, Inc., Strasbourg, France 2007 - present

GlaxoSmithKline (GSK) Pharmaceuticals, Inc., Collegeville, PA 2008 - present

GlaxoSmithKline (GSK) Pharmaceuticals, Inc., Res. Triangle Park, NC, 2008 - present

Vertex Pharmaceutical, San Diego, CA, 2008 - present

AllerQuest LLC, West Hartford, CT, 2010 - present

Diverchim, Montataire, France, 2011 - present

Sofie Biosciences, Culver City, CA, 2011 - present

 

 


CURRENT RESEARCH

 

      The majority of the research personnel in my group are currently engaged in three general fields of interest: the development of new synthetic methods, the total synthesis of biologically active natural products, and medicinal chemistry. We are pursuing the total synthesis of several promising antitumor agents, e.g., tedanolide and 13-deoxytedanolide, dichlorolissoclimide, haterumaimide E, the auripyrones, the cucurbitacins, rugulosone, and gymnostatin G. The use of epoxide rearrangements in synthesis, e.g., the non-aldol aldol process, and others, is under investigation as well, especially for the synthesis of new antibiotics of the erythromycin class. We are also studying the use of various reactions (e.g., Diels-Alder reactions and [3,3] rearrangements) for the synthesis of biologically active molecules, e. g., the immunosuppressive agent brasilicardin A; the antibiotic fusidic acid; the acetylcholinesterase inhibitors, the arisugacins and territrems; the antibacterial agent mycosporulone; and multiple drug resistance reversing agents such as welwitindolinone C. In particular, we are developing the mixed Lewis acid system, 5:1 AlBr3:AlMe3, in a variety of reactions, e.g., cycloadditions, nucleophilic additions, etc. We are developing new processes for the efficient synthesis of polyhydroxylated steroids, e.g., the cardioactive agent ouabain and the anticancer agent rhodexin A. We have several collaborative programs in medicinal chemistry, e.g.: a) the preparation and testing of novel small molecule androgen receptor antagonists which are very active at inhibiting the growth of castration-resistant prostate cancer; b) the preparation of various naturally occurring oxidation products of arachidonic acids, epoxy isoprostanes such as PEIPC (which are involved in the onset of atherosclerosis); c) the development of a new method of delivering antibacterial agents to resistant bacterial strains; d) the preparation and testing of new selective binders for the estrogen receptor as potential anti-breast cancer agents; e) ) the preparation and testing of small molecules which differentiate stem cells into osteoblasts for bone growth; f) the design and preparation of small molecule inhibitors of the growth of several enveloped viruses, e.g., Nipah virus; g) the design and preparation of small molecule inhibitors of mycolyl transferase as anti-TB agents; h) the design and synthesis of novel small molecule radiomitigators; and i) the preparation of molecules that bind to the Sortase-A binding pocket to determine the structure of this important medicinal target and as potential antibacterial agents. We are also investigating the development of new reaction for synthesis, e.g., the non-aldol aldol process, the bridged Robinson annulation, and the mixed Lewis acid Diels-Alder process.




OTHER PUBLICATIONS


1.  M. E. Jung, "An Improved Procedure for the Conversion of Amines to Alcohols at Low Temperature; New Synthesis of Alkenes and Alkynes from Amines," Chemtracts 1990, 3, 392.

 

2.  M. E. Jung, "Iodomethyl Methyl Ether," Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd., 1995.

 

3.  M. E. Jung, "Trimethylsilyl iodide," Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd., 1995.

 

4.  M. E. Jung, "1-Trimethylsilyloxy-1,3-butadiene," Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd., 1995.

 

5.  M. E. Jung, "2-Trimethylsilyloxy-1,3-butadiene," Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd., 1995.

 

6.  M. E. Jung, "Triphenylcarbenium Tetrafluoroborate," Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd., 1995.

 

7.  W. J. Wechter, E. D. Murray, Jr., D. Kantoci, and M. E. Jung, "Characterization of Two New Endogenous Natriuretic Factors," Abstract, 29th Annual Meeting, American Society of Neurology, November 1996.

 

8.  Crostic No. 49 in Crostics, No. 115, Simon & Schuster, New York, NY, ed. T. H. Middleton, 1996.

 

9.  S. E. Denmark, M. E. Jung, A. Pfaltz, B. Giese, "Laudio for Professor Doctor Albert Eschenmoser," Synlett 1999, III.

 

10.  M. E. Jung, "Tungsten Hexachloride," Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd., 2006.




MEETING ABSTRACTS

1. Richardson, J. A.; Amantea, C. M.; Nguyen, K.; Jung, M. E.; Hahn, T. J.; Parhami, F. "Characterization of osteogenic oxysterols and their molecular mechanism(s) of action,"  J. Bone Mineral Res. 2005, 20, S414-S415 Suppl. 1.

2. Wechter, W. J.; Murray, E. D.; Kantoci, D.; Jung, M. E. "Characterization of two new endogenous natriuretic factors,"  J. Am. Soc. Nephrol. 1996, 7, A2867-A2867.


 

 

SHORT COURSES

 

1.  Nov. 1980:    Upjohn Co., Kalamazoo, MI, "New Advances in the Use of Diels-Alder Reactions in Synthesis."

 

2.  Sept. 1985:    American Cyanamid Co., Agricultural Research Division, Princeton, NJ, "Silicon in Organic Synthesis."

 

3.  Sept. 1987:    Zhongshan University, Guangzhou, PRC, "Modern Organic Synthesis."

 

4.  Sept. 1987:    Zhongshan University, Guangzhou, PRC, "Silicon in Organic Synthesis."

 

5.  April 1996:    3M, St. Paul, MN, "Strategy and Design in Organic Synthesis."

 

6.  April 1998:    3M, St. Paul, MN, "New Methods in Heterocyclic Chemistry."

 

7.  Dec. 1999:    Neurocrine Biosciences, "Introduction to Modern Heterocyclic Chemistry."

 

8.  Mar. 2003:    Université Pierre et Marie Curie, Paris, "Modern Heterocyclic Chemistry."


9.  May 2008:    Vertex, Inc., San Diego, "Modern Heterocyclic Chemistry."


 


PATENTS AND APPLICATIONS


1. Cross, B.; Los, M.; Doehner, R. F., Jr.; Ladner, D. W.; Johnson, J. L.; Jung, M. E.; Kamhi, V. M.; Tseng, S. S.; Finn, J. M.; Wepplo, P. J. (Assignee: American Cyanamid Company) ÒPreparation of Novel Fused Imidazolinylpyridines as Herbicides,Ó Eur. Pat. Appl. 1987, EP 227932 A1, CAN 108:21884.

2. Jung, M. E.; Gardiner, J. M. (Assignee: The Regents of the University of California) ÒProcess for the Synthesis of 2Õ,3Õ-Dideoxynucleosides,Ó US Patent 5,220,003 (June 15, 1993).

3. Cross, B.; Los, M.; Doehner, R. F., Jr.; Ladner, D. W.; Johnson, J. L.; Jung, M. E.; Kamhi, V. M.; Tseng, S. S.; Finn, J. M.; Wepplo, P. J. (Assignee: American Cyanamid Company) Ò(2-Imidazolin-2-yl) Fused Heteropyridine Compounds, Intermediates for the Preparation of and Use of Said Compounds as Herbicidal Agents,Ó US Patent
5,252,538 (October 12, 1993).

4. Harrington, P. E.; Jung, M. E. (Assignee: American Cyanamid Company) ÒStereoselective Bromination of β-Ribofuranosyl Amide: Synthesis of Herbicidal Analogues of Hydantocidin,Ó US Patent 5,354,868 (October 11, 1994).

5. Jung, M. E.; DÕAmico, D. C. (Assignee: The Regents of the University of California) ÒStereospecific Synthesis of Aldols,Ó US Patent 5,426,206 (June 20, 1995).

6. Harrington, P. E.; Jung, M. E. (Assignee: American Cyanamid Company) ÒProcess and Intermediates for the Preparation of (+)-Hydantocidin and Analogs Thereof,Ó US Patent 5,543,510 (August 6, 1996).

7. Jung, M. E.; Cook, P. D.; Kawasaki, A. M. (Assignee: Isis Pharmaceuticals) ÒMethod for Removing Unreacted Electrophiles from a Reaction Mixture,Ó US Patent 5,632,898 (May 27, 1997).

8. Fraser, A. S.; Manoharan, M.; Cook, P. D.; Jung, M. E.; Kawasaki, A. M. (Assignee: Isis Pharmaceuticals) ÒPreparation of DNA having improved hybridization affinity and nuclease resistance via alkylation of nucleosides with cyclic sulfates,Ó US Patent 6,277,982 (August 21, 2001).

9. Manoharan, M.; Guzaev, A.; Jung, M. E.; Just, G.; Roland, A.; Wang, J. (Assignee: Isis Pharmaceuticals) ÒSolid phase synthesis of alkylphosphonate-linked oligodeoxyribonucleotides,Ó US Patent 6,486,313 (November 26, 2002). PCT Int. Appl. WO2000049032.

10. Jung, M. E.; Xu, Y. (Assignee: The Regents of the University of California) ÒSynthesis of L-Ribose and 2-Deoxy-L-Ribose from D-Ribose,Ó PCT Int. Appl. WO9839347, A2 19980911.

11. Manoharan, M.; Just, G.; Guzaev, A.; Roland, A.; Wang, J.; Jung, M. E. (Assignee: Isis Pharmaceuticals) ÒOligonucleotides having alkylphosphonate linkages and methods for their preparation,Ó US Patent 7,049,432 (May 23, 2006).

12. Finn, J.; Morytko, M.; Parr, I. B.; Jung, M. (Assignee: Cubist Pharmaceuticals) ÒPreparation of novel depsipeptides as antibacterials,Ó PCT Int. Appl. WO200314147 A1 20030220.

13. Morytko, M.; Zhang, Y.; Jung, M.; Finn, J.; Bouchard, M. (Assignee: Cubist Pharmaceuticals) ÒPreparation of lipopeptide stereoisomeric compounds as antibacterial agents,Ó PCT Int. Appl. WO200317924, A2 20030306.

14. Sawyers, C. L.; Jung, M. E.; Chen, C. D.; Ouk, S.; Welsbie, D.; Tran, C.; Wongvipat, J.; Yoo, D. (Assignee: The Regents of the University of California) ÒDiarylhydantoin Compounds,Ó US Patent 7,709,517 (May 4, 2010).

15. Jung, M. E.; Ouk, S.; Sawyers, C. L.; Chen, C. D.; Welsbie, D. (Assignee: The Regents of the University of California) ÒMethods and Materials for Assessing Prostate Cancer Therapies and Compounds,Ó US Patent 7,718,684, (May 18, 2010).

16. Jung, M. E.; Ouk, S.; Sawyers, C. L.; Chen, C. D.; Welsbie, D. (Assignee: The Regents of the University of California) ÒMethods and Materials for Assessing Prostate Cancer Therapies and Compounds,Ó PCT Int. Appl. WO 2005099693 A2 20051027 CAN 143:432632 AN 2005:1154369.

17. Manoharan, M.; Jung, M. E.; Rajeev, K. G.; Pandey, R. K.; Wang, G. (Assignee: Alnylam Pharmaceuticals) ÒProcesses and Reagents for Oligonucleotide Synthesis and Purification,Ó US Patent Appl. 20050267300, (December 1, 2005).

18. Whitten, J. P.; Pierre, F.; Regan, C.; Schwaebe, M.; Yiannikouros, G. P.; Jung, M. (Assignee: Cylene Pharmaceuticals) ÒMethod for Converting Quinolone Esters into Quinolone Amides,Ó US Patent 7,652,134 (January 26, 2010).

19. Manoharan, M.; Jung, M. E.; Rajeev, K. G.; Pandey, R. K.; Wang, G. (Assignee: Alnylam Pharmaceuticals) ÒProcess and Reagents for Oligonucleotide Synthesis and Purification,Ó PCT Int. Appl. WO 2005097817, A2 20051020.

20. Manoharan, M.; Jung, M. E.; Rajeev, K. G.; Pandey, R. K.; Wang, G. (Assignee: Alnylam Pharmaceuticals) ÒProcesses and Reagents for Desilylation of Oligonucleotides,Ó US Patent Appl. 20090005549, (January 1, 2009).

21. Manoharan, M.; Jung, M. E.; Rajeev, K. G.; Pandey, R. K.; Wang, G. (Assignee: Alnylam Pharmaceuticals) ÒProcesses and Reagents for Sulfurization of Oligonucleotides,Ó US Patent Appl. 20090187027 (July 23, 2009).

22. Whitten, J. P.; Pierre, F.; Regan, C.; Schwaebe, M.; Yiannikouros, G. P.; Jung, M. E. (Assignee: Cylene Pharmaceuticals) ÒPreparation of fused quinolone analogs which inhibit cell proliferation and/or induce cell apoptosis,Ó US Patent Appl. 20060074089. Cont.-in-part of U.S. Ser. No. 149,007. US 2006074089 A1 20060406 CAN 144:370091 AN 2006:322120.

23.Whitten, J. P.; Pierre, F.; Regan, C.; Schwaebe, M.; Yiannikouros, G. P.; Jung, M. ÒPreparation of fused quinolone analogs which inhibit cell proliferation and/or induce cell apoptosis,Ó PCT Int. Appl. WO 2006034113 A2 20060330 CAN 144:350684 AN 2006:301302.

24. Whitten, J. P.; Pierre, F.; Regan, C.; Schwaebe, M.; Yiannikouros, G. P.; Jung, M. E.; Nagasawa, J. Y.; Chua, P. (Assignee: Cylene Pharmaceuticals) ÒProcess for the Preparation of Benzothiazole and Phenoxazine Compounds,Ó US Patent Appl. 2006063761 A1 20060323 CAN 144:331460 AN 2006:273183.

25. Parhami, F.; Jung, M. E.; Dwyer, J. R.; Nguyen, K. (Assignee: The Regents of the University of California) ÒOxysterol Compounds and the Hedgehog Pathway,Ó US Patent Appl. 20100034781 (February 11, 2010).

26. Sawyers, C. L.; Jung, M. E.; Chen, C. D.; Ouk, S.; Welsbie, D.; Tran, C.; Wongvipat, J.; Yoo, D. (Assignee: The Regents of the University of California) ÒDiarylthiohydantoin Compounds,Ó PCT Int. Appl. WO 2006124118 A1 20061123.

27. Parhami, F.; Jung, M. E.; Dwyer, J. R.; Nguyen, K. (Assignee: The Regents of the University of California) ÒOxysterol Compounds and the Hedgehog Pathway,Ó PCT Int. Appl. WO 2007098281 A2 20070830.

28. Jung, M. E.; Yoo, D.; Sawyers, C. L.; Tran, C. (Assignee: The Regents of the University of California) ÒDiarylthiohydantoin Compounds,Ó US Patent Appl. 20070254933 A1 20071101.

29. Jung, M. E.; Yoo, D.; Sawyers, C. L.; Tran, C. (Assignee: The Regents of the University of California) ÒDiarylthiohydantoin Compounds,Ó US Patent Appl. 20080139634.

30. Jung, M. E.; Sawyers, C. L.; Ouk, S.; Tran, C.; Wongvipat, J. (Assignee: The Regents of the University of California) ÒAndrogen Receptor Modulators for the Treatment of Prostate Cancer and Androgen Receptor-Associated Diseases,Ó PCT Int. Appl. WO 2007126765 A2 20071108.

31. Jung, M. E.; Yoo, D.; Sawyers, C. L.; Tran, C. "Diarylhydantoin Compounds as Androgen Receptor Modulators,Ó (Assignee: The Regents of the University of California) PCT Int. Appl. WO 2009055053 A2 20090430.

32. Sawyers, C. L.; Jung, M. E.; Yoo, D.; Tran, C. (Assignee: The Regents of the University of California) "Diarylhydantoin Compounds,Ó US Patent Appl. 20090111864.

33. Parhami, F.; Jung, M. E.; Nguyen, K.; Yoo, D.; Kim, W.-K. (Assignee: The Regents of the University of California) ÒOxysterols for Activation of Hedgehog Signaling, Osteoinduction, Antiadipogenesis, and Wnt Signaling,Ó PCT Int. Appl. WO 2009073186 A1 20090611.

34. Lee, B; Jung, M. E.; Wolf, M. C.; Zhang, T. (Assignee: The Regents of the University of California) ÒNovel Antiviral Agents for Enveloped Viruses,Ó PCT Int. Appl. WO 2010044924 A1 20100422.

35. Schiestl, R. H.; Rivina, Y. O.; Jung, M. E. (Assignee: The Regents of the University of California) ÒCompounds for Mitigating Radiation-Induced Tissue Damage and Lethality,Ó 356115-v1-105837-4.

36. Jung, M. E.; Clubb, R. T.; Yi, S. W.; Suree, N.; Clemens, J. J. (Assignee: The Regents of the University of California) "Sortase A Inhibitors," PCT Int. Appl. PCT/US10/46394.

37. Manoharan, M.; Rajeev, K. G.; Jayaraman, M.; Butler, D.; Jung, M. E. (Assignee: Alnylam Pharmaceuticals) ÒLipid compositions for the delivery of nucleic acid therapeutics,Ó PCT Int. Appl. WO 2010129709.

38. Parhami, F.; Kim, W.-K.; Jung, M. E.; Nguyen, K. (Assignee: The Regents of the University of California) ÒInhibition of peroxisome proliferator activated receptor gamma expression in preadipocyte cells by oxysterols,Ó PCT Int. Appl. WO 2011006087.

Summary: 13 issued patents; 25 patent applications (23 pending)



 

INVITED LECTURES

 

539 Lectures, seminars, and presentations at international and national chemical meetings and symposia, academic institutions, and industrial institutions from 1973-2011.